The latest price target for Sage Therapeutics (NASDAQ:SAGE) was reported by Scotiabank on February 12, 2025. The analyst firm set a price target for $12.00 expecting SAGE to rise to within 12 months (a possible 63.71% upside). 66 analyst firms have reported ratings in the last year.

The latest analyst rating for Sage Therapeutics (NASDAQ:SAGE) was provided by Scotiabank, and Sage Therapeutics maintained their sector outperform rating.

The last upgrade for Sage Therapeutics Inc happened on November 21, 2024 when RBC Capital raised their price target to $4. RBC Capital previously had an underperform for Sage Therapeutics Inc.

The last downgrade for Sage Therapeutics Inc happened on October 4, 2024 when RBC Capital changed their price target from $10 to $4 for Sage Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sage Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sage Therapeutics was filed on February 12, 2025 so you should expect the next rating to be made available sometime around February 12, 2026.

While ratings are subjective and will change, the latest Sage Therapeutics (SAGE) rating was a maintained with a price target of $14.00 to $12.00. The current price Sage Therapeutics (SAGE) is trading at is $7.33, which is out of the analyst’s predicted range.